KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Net Margin (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Net Margin for 13 consecutive years, with 421.6% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 37249.0% to 421.6% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 242.77% through Dec 2025, up 88948.0% year-over-year, with the annual reading at 242.77% for FY2025, 89027.0% up from the prior year.
  • Net Margin hit 421.6% in Q4 2025 for Arbutus Biopharma, up from 1461.25% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 23.3% in Q2 2025 to a low of 1472.89% in Q3 2024.
  • Historically, Net Margin has averaged 697.67% across 5 years, with a median of 704.42% in 2021.
  • Biggest five-year swings in Net Margin: tumbled -104129bps in 2024 and later surged 116976bps in 2025.
  • Year by year, Net Margin stood at 682.94% in 2021, then soared by 49bps to 351.19% in 2022, then crashed by -156bps to 900.33% in 2023, then grew by 12bps to 794.09% in 2024, then soared by 47bps to 421.6% in 2025.
  • Business Quant data shows Net Margin for ABUS at 421.6% in Q4 2025, 1461.25% in Q3 2025, and 23.3% in Q2 2025.